Dermatomyositis Market to Surpass US$ 696.57 Mn by 2030

Global Dermatomyositis Market, by Type (Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS)), by Treatment Type (Anti-inflammatory Medication, Immunosuppressive Drugs, Immunoglobulin, and Others (Plasma Exchange, Monoclonal antibody among others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) is estimated to be valued at US$ 493.15 Million in 2022 and projected to exhibit a CAGR of 4.4% during the forecast period (2022-2030).

Key players operating in the global dermatomyositis market are focusing on the development of novel treatments for dermatomyositis. The key therapeutic compounds currently in the pipeline market for treating dermatomyositis include receptor agonists, enzyme inhibitors, receptor antagonists, protein and peptide inhibitors, biological factor inhibitors among others. Several market players are engaged in conducting clinical trials to evaluate the safety and efficacy of new drugs developed for the treatment of dermatomyositis. For instance, in July 2017, Neovacs, a pioneer in active immunotherapies for the treatment of autoimmune illnesses, announced that the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for IFNalpha Kinoid for the treatment of dermatomyositis, allowing the company to begin its Phase IIa clinical study in the U.S.

Global Dermatomyositis Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has affected various industries globally. Key players operating in the global dermatomyositis market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of September 19, 2022, are approximately 609,848,852 confirmed cases with 6,507,002 deaths.

The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs (clinical research organizations), and other organizations that support drug development shifted to remote working environments. According to Lancet, an estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.

In an April 2020 study published in Lancet investigative sites demonstrated flexibility and ingenuity in adopting new approaches in order to cope with challenges presented by the COVID, with over half of investigative sites transitioning to virtual approaches to interact with patients. More recently, follow-up studies performed in August 2020 have identified persistent impact of COVID, with over 60% reporting an average or greater level of impact on ongoing trials and initiation of new trials. Respondents specifically highlighted challenges in patient enrollment and recruitment.

Browse 35 Market Data Tables and 31 Figures spread through 225 Pages and in-depth TOC on “Global Dermatomyositis Market” - Forecast to 2030, Global Dermatomyositis Market, by Type (Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS)), by Treatment Type (Anti-inflammatory Medication, Immunosuppressive Drugs, Immunoglobulin, and Others (Plasma Exchange, Monoclonal antibody among others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Forecast to 2030

To know the latest trends and insights prevalent in the Global Dermatomyositis Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/dermatomyositis-market-5250

Key Takeaways of the Global Dermatomyositis Market:

• Global dermatomyositis market is expected to exhibit a CAGR of 4.4% during the forecast period, owing to increasing adoption of inorganic growth strategies such as merger and acquisitions by key players. In July 2020, Astrazeneca Plc, a multinational pharmaceutical and biotechnology company, acquired Alexion, a U.S.-based pharmaceutical company specializing in orphan pharmaceuticals to treat rare diseases such as dermatomyositis, to expand AstraZeneca’s product portfolio
• Among type, Adult dermatomyositis segment is expected to dominate the global dermatomyositis market in the forecast period, owing to increasing research and development activities by key players, which is expected to drive the segment growth over the forecast period. For instance, in March 2021, Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company, announced that the last subject completed the final visit in the double-blind, placebo-controlled part of the company’s Phase 3 DETERMINE study of lenabasum for the treatment of dermatomyositis. The Phase 3 trial is an international, 176-subject study evaluating the safety and efficacy of lenabasum in adult dermatomyositis.
• Major players operating in the global dermatomyositis market include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Néovacs, Horizon Therapeutics plc, and Pfizer Inc.